| NCT ID | NCT06695221 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alberta |
| Condition | Systemic Inflammatory Response |
| Study Type | INTERVENTIONAL |
| Enrollment | 156 participants |
| Start Date | 2026-03-24 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 156 participants in total. It began in 2026-03-24 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to ascertain whether traditional kefir not only enhances vascular health but also contributes to improved immune outcomes in both male and female participants at higher risk or living with Type 2 Diabetes (T2D) after 12 weeks of treatment.
Eligibility Criteria
Inclusion Criteria: 1. females and males (24-70 years old) living in Edmonton (or Edmonton area/driving distance); 2. overweight or obesity (BMI \>25 Caucasian, \>23 Asian); 3. at higher risk of T2D (fasting blood glucose ≥ 5.6 - 6.9 mmol/L or/and HbA1C ≥ 5.5 - 6.4%); or 4. with diagnosis of T2D (fasting blood glucose ≥ 7.0 mmol/L or/and HbA1C ≥ 6.5%). Exclusion Criteria: 1. a usual high intake (maximum intake 3 servings/week) of fermented foods excluding cheese (i.e., kefir, kombucha, kimchi, etc.) for the past 3 months; 2. gastrointestinal (GI) disorders of any kind; 3. being pregnant or breastfeeding; 4. monogenic dyslipidemias and endocrine disorders except for diabetes; 5. use of medications within the last 3 months (i.e., antibiotics or antifungals, corticosteroids, methotrexate, or immunosuppressive cytotoxic agents); 6. any health conditions deemed to interfere with primary outcomes at the investigator's discretion (e.g., kidney disease, liver disease, cancer, GI surgery, heavy alcohol consumption, etc.); 7. having a pacemaker or any electrical medical device that prevents the individual from undergoing the bioelectrical impedance analysis bioimmunoassay (BIA) test."
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06695221 clinical trial?
This trial is open to participants of all sexes, aged 24 Years or older, up to 70 Years, studying Systemic Inflammatory Response. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06695221 currently recruiting?
Yes, NCT06695221 is actively recruiting participants. Contact the research team at paldana@ualberta.ca for enrollment information.
Where is the NCT06695221 trial being conducted?
This trial is being conducted at Edmonton, Canada.
Who is sponsoring the NCT06695221 clinical trial?
NCT06695221 is sponsored by University of Alberta. The trial plans to enroll 156 participants.